Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Alan H, Gradman"'
Autor:
Alan H. Gradman, Jack Ishak, Joel M. Neutel, Sanjida Ali, Michael Rael, Mehul Patel, Henry Punzi, William S. Ferguson, Lynn M. Anderson
Publikováno v:
Journal of Clinical Hypertension (Greenwich, Conn.)
The single-pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β1 -selective antagonist/β3 -agonist, and valsartan (80 mg), a renin-angiotensin-aldosterone system inhibitor, is the only Food and Drug Administration-approved β-blocke
Autor:
Michael H. Kim, Wayne T. Pan, Liou Xu, David S. Kountz, James G. Stevenson, Fadia T. Shaya, Viktor V. Chirikov, Alan H. Gradman, David L. Larsen, Gary Puckrein, Michael Wysong, Jennifer Wilbanks
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 21:1034-1038
A multidimensional approach involving consideration of available resources, individual patient characteristics, patient preferences, and cost of treatment is often required to optimize clinical decision making in the management of atrial fibrillation
Autor:
Alan H. Gradman
Publikováno v:
Journal of Indian College of Cardiology. 5:S38-S42
Publikováno v:
Journal of Cardiac Failure. 20:853-863
Background Current guidelines recommend the use of intravenous (IV) vasodilators in addition to IV loop diuretics for the treatment of acute heart failure (AHF) patients without hypotension. The evidence basis for these recommendations is limited. Me
Autor:
Alan H. Gradman
Publikováno v:
Journal of the American College of Cardiology. 67(5):473-475
For the past several years, many physicians have been puzzled by the rapidly changing recommendations for the treatment of hypertension. The belief that “lower is better” has been challenged, and emphasis has been placed upon the risks accompanyi
Autor:
Alan H. Gradman
Publikováno v:
Current Hypertension Reports. 19
BP treatment thresholds/targets determine when to initiate treatment and to what level BP should be reduced. The Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) recommended a target
Autor:
Alan H. Gradman, Jan Basile
Publikováno v:
Journal of the American Society of Hypertension. 8:770-774
Autor:
Thomas D, Giles, Michael A, Weber, Jan, Basile, Alan H, Gradman, David B, Bharucha, Wei, Chen, Manoj, Pattathil, Chandar, Abboy
Publikováno v:
The Lancet. 383:1889-1898
The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. We assessed the efficacy and safety of a fixed-dose combina
Autor:
Marie-Hélène Lafeuille, Hélène Parisé, Heather Falvey, Mei Sheng Duh, Patrick Lefebvre, Alan H. Gradman
Publikováno v:
Hypertension. 61:309-318
This study evaluated the effects of initial versus delayed treatment with a drug combination on blood pressure (BP) control and the risk of cardiovascular (CV) events in hypertensive patients. Clinical trials suggest that the time to BP control is an
Autor:
Alan H. Gradman
Publikováno v:
European heart journal. 37(12)
This editorial refers to ‘Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial’[†][1], by G. Mancia et al ., on page 955. Blood pressure (BP) targets are practical objectives which ai